1 Worldwide, it is estimated that 16.4 million people have had an RVo (5.2 per 1,000 persons), 13.9 million with BRVo (4.42 per 1,000 persons), and 2.5 million with cRVo (0.80 per 1,000 persons).
of BRvO is determined by the amount of pre-existent arterial disease. measurements of the area of RNp on fluorescein angiograms are greater in patients with BRvO compared with cRvO, but it appears likely that this is an artifact of ascertainment, because measurements are made in the posterior pole of the retina within the temporal arcade vessels; there is clearly more posterior RNp on average in patients with BRvO, but wide-angle fluorescein angiography suggests that total RNp is greater on average in patients with cRvO.
Substantial progress has been made elucidating the pathogenesis of edema in RvO. Retinal ischemia causes high levels of vascular endothelial growth factor (veGF), which is the major cause of excessive vascular permeability. Blockade of veGF causes rapid reduction in edema and speeds resolution of intraretinal hemorrhages. thus, veGF contributes to both edema and intraretinal hemorrhages. in addition, high levels of veGF contribute to worsening of RNp over time. thus, the occlusion causes variable amounts of retinal ischemia that increases levels of veGF and then it is the high veGF levels that become the driver of the disease. this has important implications regarding treatment, which is discussed below.
Treatment

Laser Photocoagulation
the demonstration that focal/grid laser photocoagulation treatment provided benefit in diabetic macular edema (Dme), suggested that it might also provide benefit in other retinal vascular diseases including BRvO. however, compared with Dme, there is often more intraretinal hemorrhage in the macula of patients with acute BRvO, which can make laser photocoagulation more risky. Normally laser light is absorbed by the pigment of the retinal pigmented epithelium and converted to heat resulting in damage to photoreceptors with sparing of the overlying retina. if there is intraretinal blood where laser is delivered, hemoglobin absorbs the laser light and converts it to heat in the inner retina resulting in a superficial burn, which may damage ganglion cells and their axons, causing a permanent scotoma and reducing the damage in the photoreceptor layer thereby failing to reduce oxygen utilization by photoreceptors-the objective of the treatment. also, compared with Dme, the leakage in BRvO is more confluent, involving telangiectatic retinal vessels in the half of the macula on the side of the occlusion.
in the late 1970s, the BRvO Study Group 8 designed a protocol to test the effect of grid laser photocoagulation throughout the area of diffuse fluorescein leakage in the macula, avoiding the foveal avascular zone, in BRvO patients. to allow reduction in hemorrhage and to exclude patients with spontaneous improvement, all patients were observed for 3 months after which patients who had macular edema (me) causing reduction of best-corrected visual acuity (Bcva) to ≤20/40 were randomized to laser (n=69) or observation (n=70). the duration of disease at randomization ranged from 3 to 18 months. patients randomized to laser, who had substantial intraretinal hemorrhage in the macula, had laser deferred until the hemorrhages had cleared sufficiently to allow laser to be performed safely. patients were evaluated by fluorescein angiography 4 months after laser and additional grid laser photocoagulation was applied if untreated leaking areas were present with continued reduction in Bcva. Of the 69 patients in the laser group, 53, 10, two, and four received one, two, three, and five treatments, respectively. the mean follow up was 3.1 years, 115 patients had at least two years of follow up, and 78 had 3 years of follow up. visual outcomes were reported only for the 78 patients who had a 3-year visit. compared with the control group in which the mean improvement from baseline was 0.23 lines and 37 % gained ≥2 lines, in the laser group the mean improvement from baseline is another anti-vEGF agent that has been approved for treatment of
NvaMD. it provides benefit in patients with cRvO and is currently being investigated in patients with BRvO.
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Intraocular Steroids
Triamcinolone Acetonide there was also a corresponding increase in iOp parallel to drug activity and observed letter gain, with the percentage of patients with iOp of ≥35 mmhg or ≥25 mmhg, or an iOp increase of >10 mmhg increasing at month 2 in the implant treatment groups and at month 8 for those patients receiving treatment at month 6. there was a higher rate of cataract progression with the increased use, and the higher dose, of dexamethasone implant. there was no effect of the dexamethasone implant on progression of RNp as observed at month 6. there was no effect of the dexamethasone implant on progression of RNp as observed at month 6. 
Prognostic Factors
Older age, history of coronary disease, and longer duration of edema are associated with reduced visual acuity outcomes in BRvO. 8, 27 BRvO patients with a shorter duration of disease are more likely to have a higher visual acuity gain and better final visual acuity when treated with ranibizumab or a dexamethasone implant. 10, 13, 28 poor visual outcome correlates with increased foveal avascular zone (FaZ) 29 or disruption of perifoveal capillaries seen in fluorescein angiograms. [30] [31] [32] Similarly in BRvO patients treated with grid laser, those with intact perifoveal capillaries have a better visual prognosis than those with perifoveal capillary disruption. 31 Nonperfusion is a significant baseline factor for development of disc or retinal neovascularization in patients with BRvO with the highest risk at ≥5.5 disc areas. 33 the use of optical coherence tomography (Oct), particularly spectral domain Oct (SD-Oct), has brought attention to a correlation between visual acuity and the visualization of inner segment/outer segment (iS/ OS) and/or external limiting membrane (elm) at the fovea. [34] [35] [36] it is clear that absence of the iS/OS and/or elm on Oct is strongly correlated with poorer Bcva at baseline in the presence of edema, and after resolution of edema following treatment. [34] [35] [36] however, absence of iS/OS visualization in a patient with edema may be due to damage/loss of photoreceptor cells or may be due to disarrangement of the photoreceptors due to fluid.
patients with intact iS/OS and elm at baseline have been reported to fare better in one retrospective analysis, which used a multiple regression model with cpt at baseline as a predictor variable to suggest that baseline iS/OS and elm status are predictors of final Bcva independent of thickness, 35 
